We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status.
Trestle Biotherapeutics is a Y Combinator company in the Winter 2021 batch. Its directory entry describes it as: Bioengineered kidneys for patients with kidney failure. The founders listed are Ben Shepherd (Founder), Alice Chen (Founder) (Y Combinator directory entry, March 16, 2021).
Sell to companies like Trestle Biotherapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2021-03-16 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Trestle Biotherapeutics.
Free to see. No signup.
More on Trestle Biotherapeutics and the records around it.
Get an email when Trestle Biotherapeutics changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Trestle Biotherapeutics raises, hires or launches. No email unless you switch it on.
Watch Trestle Biotherapeutics →Get the full cited report on Trestle Biotherapeutics
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Trestle Biotherapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
We are developing an implantable therapeutic tissue that will be surgically delivered to patients suffering from end stage renal disease. Upon implantation, this tissue will supplement the patient's renal function, eliminating their dependency on dialysis and improving their disease status. This has the potential to not only get these patients off dialysis - a significant impact for them and their families - but to greatly extend the time required before kidney transplantation is essential.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Trestle Biotherapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Trestle Biotherapeutics covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Trestle BiotherapeuticsYou get an alert in MentionFox the next time this company shows up.
If you're behind Trestle Biotherapeutics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Trestle Biotherapeutics. With no account yet, you sign up free and land on the result.
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-trestle-biotherapeutics